Warning: parse_url(http:///www.achillion.com/pipeline) [function.parse-url]: Unable to parse URL in /home/content/20/8524720/html/wp-content/plugins/jetpack/class.media-extractor.php on line 208

Warning: parse_url(http:///www.achillion.com/pipeline) [function.parse-url]: Unable to parse URL in /home/content/20/8524720/html/wp-content/plugins/jetpack/class.media-extractor.php on line 208

Warning: parse_url(http:///www.achillion.com/pipeline) [function.parse-url]: Unable to parse URL in /home/content/20/8524720/html/wp-content/plugins/jetpack/class.media-extractor.php on line 208

Warning: parse_url(http:///www.achillion.com/pipeline) [function.parse-url]: Unable to parse URL in /home/content/20/8524720/html/wp-content/plugins/jetpack/class.media-extractor.php on line 208

Life Science Stocks Perky Today: ACHN,ALXN, AMRI,CBST,PCYC,OPTR

Biotech Rally Takes Sector to New Highs

After a brief lull many biopharmaceuticals stocks are rallying over 2% today. Recently we reiterated Cubist (CBST $45.38) up 4.4% and Optimer (OPTR $12.62) up 3.34% and both are among big movers today. Taking the lead from some undiscovered small to mid cap stocks which have recently taken off we are adding Achillion (ACHN $8.60) today.

Achillion is a play on the huge potential for HCV therapeutics and has two Phase 2 clinical milestones in 2013, the first for Phase 2 data  in April for its ACH-3102 combo drug with ribavirin. The Company raised $125M last week at a price of $8.40.

Comments are closed.